bioRxiv Science⌕ Search

Biology subjects

Hickson, I.

Publications and source records attributed to Hickson, I..

2 recordsLinked to original sources

Exercise serum promotes DNA damage repair and upregulates DNA repair gene PNKP in colon cancer cells

Exercise protects against colon cancer progression, but the underlying biological mechanisms remain incompletely understood. One proposed mechanism is the release of bioactive molecules into the interstitium and systemic circulation during exercise, which may act directly on precancerous or tumour cells to suppress DNA damage, inhibit proliferation, and preserve genomic stability. Here, we evaluated the effects of exercise-conditioned human serum on DNA damage kinetics and transcriptomic signatures in colon cancer cells. Blood samples were collected from 30 participants (age 50-78 years, body mass index [≥]25 kg/m2) before and immediately after a maximal incremental cycling test. LoVo cells were exposed to pre- or post-exercise serum, treated with 2 Gy irradiation, and assessed for {gamma}-H2AX foci over 24 hours. Compared to pre-exercise serum, post-exercise serum significantly reduced {gamma}-H2AX foci at 6 hours (p=0.024) and decreased the area under the curve (AUC, p=0.014), indicating accelerated DNA repair. Post-exercise serum also increased expression of the DNA repair protein PNKP in LoVo cells, both with and without irradiation (p=0.007 and p=0.029, respectively). Transcriptomic analysis revealed upregulation of mitochondrial energy metabolism and downregulation of cell cycle and proteasome-related pathways. These findings suggest that acute exercise elicits systemic responses that enhance DNA repair and shift colon cancer cells towards a less proliferative transcriptomic state under sublethal genotoxic stress, offering a potential mechanistic explanation for the protective effects of exercise against colorectal carcinogenesis.

cancer biology↗

Structural, biophysical and biological analysis and characterisation of IRF4 DNA-binding domain mutations associated with multiple myeloma

IRF4, a transcription factor in the interferon regulatory factor family, is a key regulator in immune cell differentiation indicated to have an essential role in the development of lymphoid malignancies. Genome-wide association studies previously identified a set of overlapping mutations within the IRF4 DNA-binding domain in T-cell lymphoma and multiple myeloma, several of which appeared to be associated with better prognosis. Mapping these mutations to the known crystal structure of the IRF4:PU.1:DNA ternary complex and a new structure of the IRF4 DNA-binding domain in the apo state suggested they might interfere with DNA-binding, directly or via destabilisation of domain structure. We characterised these cancer-associated IRF4 mutants experimentally using the recombinant IRF4 DNA-binding domain (DBD) in vitro and examined the clinically relevant mutant K123R in cellulo. Using fluorescence polarisation, surface plasmon resonance, differential scanning fluorimetry and molecular dynamics, we find that mutation may give rise to significant differences in DNA-binding kinetics and thermal stability without compromising the affinity of IRF4 DNA-binding. The K123R IRF4 mutant showed increased transcriptional activity via a luciferase reporter assay and increased nuclear partitioning, which may be preferentially selected for in multiple myeloma. We discuss our observations in relation to the improved prognosis conferred by this mutation.

biophysics↗